SIGA TECHNOLOGIES INC — Director's Dealing 2018

Sep 13, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: SIGA TECHNOLOGIES INC (SIGA)
CIK: 0001010086
Period of Report: 2018-09-11

Reporting Person: Hruby Dennis E (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-09-11	Common Stock, par value $.0001 per share	M	18174	$3.53	Acquired	226314	Direct
2018-09-11	Common Stock, par value $.0001 per share	F	8853	$7.16	Disposed	217461	Direct
2018-09-11	Common Stock, par value $.0001 per share	M	50000	$4.7	Acquired	267461	Direct
2018-09-11	Common Stock, par value $.0001 per share	F	32821	$7.16	Disposed	234640	Direct
2018-09-11	Common Stock, par value $.0001 per share	M	25000	—	Acquired	259640	Direct
2018-09-11	Common Stock, par value $.0001 per share	F	12175	$7.16	Disposed	247465	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-09-11	Stock-Settled Stock Appreciation Rights	$3.53	M	37500	Disposed	2022-02-02	Common Stock, par value $.0001 per share (37500)	Direct
2018-09-11	Stock Option (Right to buy)	$4.7	M	50000	Disposed	2019-03-05	Common Stock, par value $.0001 per share (50000)	Direct
2018-09-11	Restricted Stock Units	$	M	25000	Disposed		Common Stock, par value $.0001 per share (25000)	Direct

Footnotes

F1: This Form 4 reports the exercise of 37,500 stock-settled appreciation rights ("SSARs") for shares of common stock of SIGA Technologies, Inc. (the "Issuer") granted on February 12, 2012 and the related surrender to the Issuer of 8,853 shares of common stock of the Issuer by the Reporting Person in order to satisfy certain tax withholding obligations of the Issuer associated with the exercise of SSARs and the consequent issuance of common stock of the Issuer. No shares of common stock of the Issuer were sold by the Reporting Person in a market transaction.

F2: Each SSAR consists of the right to receive an amount, in common stock, equal to the excess of the fair market value of a share of common stock of the Issuer (subject to a cap on the fair market value at $7.00 per share) on the date of exercise over the exercise price of such SSAR. The number of shares of common stock issued was determined by dividing the total of all exercised SSARs by the fair market value of a share of common stock of the Issuer on the date of exercise.

F3: The SSARs vested in equal yearly installments over a period of three (3) years, with the first 1/3 of such SSARs vesting on February 2, 2013, the second 1/3 of such SSARs vesting on February 2, 2014, and the remaining 1/3 of such SSARs vesting on February 2, 2015.

F4: This Form 4 reports the exercise of options for 50,000 shares of common stock of the Issuer granted on March 5, 2009 and the related surrender to the Issuer of 32,821 shares of common stock of the Issuer by the Reporting Person in order to effect the option exercise. No shares of common stock of the Issuer were sold by the Reporting Person in a market transaction.

F5: The options vested in equal yearly installments over a period of three (3) years, with the first 1/3 of such options vesting on March 5, 2010, the second 1/3 of such options vesting on March 5, 2011, and the remaining 1/3 of such options vesting on March 5, 2012.

F6: This Form 4 reports the vesting of 25,000 restricted stock units ("RSUs") granted on June 8, 2017 and the consequent issuance of common stock of the Issuer, and the related surrender to the Issuer of 12,175 shares of common stock of the Issuer by the Reporting Person in order to satisfy certain tax withholding obligations of the Issuer associated with the vesting of RSUs and the consequent issuance of common stock of the Issuer. No shares of common stock of the Issuer were sold by the Reporting Person in a market transaction. Each RSU converts into one share of common stock of the Issuer on a one for one basis.

F7: The RSUs vested upon the U.S. Food & Drug Administration's final approval of TPOXX for the treatment of orthopoxvirus infections.